Develop And Industrialize Novel Bacterial Strains At New Brisbane Facility

By Max Rossetto, Sacco System

While the Brisbane facility’s key value is facilitating development and industrialization of new bacterial strains, how this is accomplished separates it from would-be competitors. Client partnerships are built on collaboration and transparency throughout all steps, leading to a clear indication for each customer of their strain’s production-at-scale feasibility, a robust method for industrial manufacture of that strain, and precise insight into the client’s cost of goods sold (COGS) once the strain is commercialized.

Importantly, Sacco System’s partnership model is designed to work within the constraints generally faced by modern, venture-capital-funded biotechs. Specifically, the current development approach tends to pursue the minimum amount of research possible to complete Phase 1. Only after Phase 2 (because many projects fail before the end of Phase 2) does belief and investment in the project tend to solidify.

However, our approach maximizes the return on that limited early investment. Rather than using the cheapest possible setup to develop clients’ fermentation, Sacco System has recreated our production plant approach on a much smaller scale. Accordingly, integrated media preparation, fermentation and downstream mimic perfectly the industrial production setup, ensuring successful scaleup to commercial volumes. The process remains affordable and fast enough for clients to advance through Phase 1 effectively while providing a much more robust process, optimized for our highly automated production facilities in Italy and the United States.